Parameter
| Biomarker | sBCMA | Full name | Serum B-cell maturation antigen | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis，Therapeutic Efficacy Monitoring | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow | Test Sample / Technology Platform | serum | ||
| Pathobiological Mechanisms | BCMA is a surface-specific marker of plasma cells, and the level of sBCMA is positively correlated with tumor burden. | ||||
| Clinical Availability Status | study validation/early clinical | ||||
| Notes and Dynamics | In non-secretory MM, monitoring of M protein replacement; persistent elevation of sBCMA after BCMA-targeted CAR-T (Ide-cel) therapy indicates drug resistance; combination with MRD allows comprehensive assessment of disease status. | ||||